Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Preclinical Research Summary Preclinical investigations involving the individual peptides included in this formulation have provided valuable insights into their biological activity in experimental models
Today, she holds 26
Cellular and Molecular Life Sciences , 67 (1), 6371